Korean ovarian cancer Patients' Real-World experience with promising drug
NCT ID NCT06086665
Summary
This study looked at how well the drug niraparib works and how safe it is for Korean women with ovarian cancer. Researchers followed 850 women who either received niraparib as maintenance therapy or as a later treatment option. The goal was to gather real-world evidence about this drug's performance specifically in Korean patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPITHELIAL OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center
Seoul, 138-736, South Korea
Conditions
Explore the condition pages connected to this study.